Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
The research suggests antibodies like these could be key ingredients in versatile lifesaving therapeutics capable of neutralizing all members of the Ebolavirus genus.
“This is like understanding how to kill five or six birds with one stone,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and senior author of the new papers, published recently in mBio and the Journal of Infectious Diseases. “The different viruses in the Ebolavirus genus vary in their structure, but all these different viruses have the same outbreak potential. We need a therapeutic approach that can target them all.”
A major challenge in treating what we call Ebola virus is that it isn’t just one pathogen but five. Members of the genus Ebolavirus include Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus and Reston virus. Each of these viruses is up to 50 percent different in amino acid sequence, making it tough to develop broad treatment strategies. For example, the Sudan and Bundibugyo viruses were responsible for 40 percent of Ebola cases before 2013, yet current experimental Ebola therapies can’t neutralize them.
Adding to the threat, all members of the Ebolavirus genus could mutate to escape immune system defenses and fight off drug therapies.
The new research shows that antibodies that bind to a site on the viral “fusion loop” can neutralize all known ebolaviruses. The fusion loop is part of the machinery that the virus uses to fuse with human cells and initiate infection. Targeting this peptide could present an opportunity to develop a universal therapy for infections caused by all five members of the Ebolavirus genus.
For the mBio study, the researchers focused on a human antibody called ADI-15878. This antibody was found in the blood of an Ebola virus survivor and is the only human antibody ever found to neutralize all five members of the Ebolavirus genus.
So how does ADI-15878 do it?
Using a high-resolution structural technique called X-ray crystallography, the scientists modeled the interaction between the antibody and the viral glycoprotein (the protein that enables the virus to infect a cell). Ebola’s glycoprotein is covered with sugars that help to mask the virus from detection by the body’s immune system. The team observed that ADI-15878 binds directly to one of these sugars alongside a paddle-like structure on the fusion loop. Part of the antibody then dips down and binds into a pocket that is normally hidden by another part of the viral glycoprotein.
“It’s really cool to see that this antibody has found a way to bind into a cryptic, conserved pocket despite the proximity of sugars and other pieces of the virus that effectively hide this region from the immune system” says mBio study first author Brandyn West, PhD, a research associate at Scripps Research.
The researchers hypothesize that this action locks two important parts of Ebola’s fusion machinery together, making it impossible for the virus to get into human cells. The fusion loop is a key piece of the Ebola virus entry machinery, so its structure is what scientists refer to as highly conserved—meaning the virus can’t easily mutate the fusion loop to escape immune detection without compromising the ability of the virus to infect cells. If antibodies targeting this structure were included in therapies or elicited through vaccines, these antibodies should provide broad protection.
But was ADI-15878 just a one in a million antibody from a lucky human survivor?
The second paper the lab published this week in the Journal of Infectious Diseases shows that such antibodies are not out of reach. In this work, the scientists showed that a mouse which had been sequentially immunized with Ebola virus and then Sudan virus also had a broadly protective antibody response. The researchers demonstrate that an antibody, termed 6D6, from this mouse binds to the same region as ADI-15878. The immunization study provides more evidence that this part of the fusion loop is a promising target for vaccine design and therapies.
“Both the human and mouse antibodies were able to neutralize all known types of Ebola,” explains Jacob Milligan, PhD, research associate at Scripps Research and first author of the Journal of Infectious Diseases study.
It could be possible, the researchers say, for therapeutics to include antibodies that work like ADI-15878. Researchers working on Ebola vaccines could also design molecules that look like this region of the fusion loop. These molecules, called immunogens, teach the human immune system which piece of the virus to target.
“We’re hot on the trail of immunogen design strategies to produce more of these neutralizing antibodies,” Ollmann Saphire says.
The Latest on: Immunogens
[google_news title=”” keyword=”immunogens” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunogens
- Domino effect around next-generation Covid vaccine trial pushes Gritstone to cut 40% of staffon February 29, 2024 at 4:00 pm
Gritstone's experimental Covid vaccine is designed to drive both B cell and T cell immunity by using self-amplifying mRNA, or samRNA, and so-called immunogens that contain viral targets and the Spike ...
- Are We Any Closer To An HIV Vaccine?on February 28, 2024 at 8:31 am
Together with tuberculosis, HIV (the human immunodeficiency virus) is a leading infectious global health threat. In 2022, there were 1.3 million new infections and about 630,000 people died from ...
- GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78on February 23, 2024 at 4:24 pm
The average one-year price target for GeoVax Labs (NasdaqCM:GOVX) has been revised to 77.78 / share. This is an increase of 1,170.83% from the prior estimate of 6.12 dated January 16, 2024. The price ...
- Mapping the Journey to an HIV Vaccineon February 14, 2024 at 4:00 pm
These studies suggest that the rational design of an effective HIV vaccine will require directed-antigen evolution to generate HIV-envelope immunogens that will robustly bind and trigger the ...
- Scientists See an Ultra-Fast Movement in an HIV-1 Surface Proteinon February 1, 2024 at 4:00 pm
Many parts of the envelope are constantly moving to evade the immune system, but vaccine immunogens are designed to stay relatively stable. It’s not that we did anything wrong based on what we knew; ...
- Bioinformatics and Multiepitope DNA Immunization to Design Rational Snake Antivenomon January 27, 2024 at 4:00 pm
What Do These Findings Mean? These results suggest that it is possible to use some of the newest genetic techniques to design immunogens that can be used to make highly specific, toxin ...
- Study Shows Centenarians Have An Immunity That Leads To Longer Liveson April 8, 2023 at 4:03 am
What is the secret to a long and happy life? It's an age-old question that humans have pondered well throughout time. While increased susceptibility to illness is not considered abnormal as we age ...
- IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technologyon January 29, 2022 at 10:49 am
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology. “We are tremendously excited to be ...
- Ending AIDS — Is an HIV Vaccine Necessary?on February 5, 2014 at 4:00 pm
The iterative design of sequential immunogens that mimic the mutational evolution of the virus during natural infection — immunogens that could be used as a constituent of a vaccine ...
via Bing News